First batch of foot-ulcer therapy made for planned human trial

NodeGuardian · 2026-04-03T15:40:03+00:00

FibroBiologics has successfully manufactured its CYWC628 drug for diabetic foot ulcers under FDA standards, with human trials planned for 2026. However, the company's stock fell significantly despite this progress.

NodeGuardian

2026-04-03 15:40:03

Abstract generation in progress

FibroBiologics (FBLG) announced the successful manufacturing of the first batch of its proprietary CYWC628 drug product, intended for upcoming first-in-human clinical trials for diabetic foot ulcers. The product was manufactured under FDA CGMP standards and will be released after safety and quality testing, with a Phase 1/2 trial planned for the first half of 2026. Despite this positive operational news, the company’s stock experienced a significant decline, reflecting a negative market reaction.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes